Logo

STSS

Sharps Technology, Inc.

STSS

Sharps Technology, Inc. • NASDAQ
$3.23 ▼ -1.22% (-0.04)
Market Cap $91.17 M
52w High $1198.50
52w Low $2.64
Dividend Yield 0%
P/E 0
Volume 103.65K
Outstanding Shares 28.23M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.289M ▲ $111.537M ▲ $-105.333M ▼ -4.602K% ▼ $-4.33 ▼ $-105.188M ▼
Q2-2025 $222.722K ▲ $1.834M ▼ $3.559M ▲ 1.598K% ▲ $3.58 ▼ $3.7M ▲
Q1-2025 $0 $1.891M ▲ $1.929M ▲ 0% $38.62 ▲ $2.687M ▲
Q4-2024 $0 $1.885M ▲ $-4.526M ▼ 0% $-1.201K ▼ $-4.366M ▼
Q3-2024 $0 $1.821M $-1.685M 0% $-48.94 $-1.491M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $25.718M ▲ $443.96M ▲ $10.746M ▲ $433.214M ▲
Q2-2025 $8.322M ▼ $17.085M ▼ $2.546M ▼ $14.54M ▲
Q1-2025 $11.895M ▲ $18.916M ▲ $8.781M ▲ $10.135M ▲
Q4-2024 $864.041K ▼ $7.314M ▼ $5.318M ▲ $1.996M ▼
Q3-2024 $2.473M $11.254M $4.748M $6.506M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $3.559M ▲ $-1.905M ▲ $-1.486M ▼ $0 ▼ $-3.573M ▼ $-3.775M ▼
Q1-2025 $1.929M ▲ $-2.451M ▼ $-473.658K ▼ $13.953M ▲ $11.031M ▲ $-2.541M ▼
Q4-2024 $-4.526M ▼ $-1.757M ▼ $-93.478K ▼ $199.461K ▼ $-1.609M ▼ $-1.827M ▼
Q3-2024 $-1.685M ▲ $-1.643M ▼ $-50.304K ▲ $2.736M ▼ $989.903K ▲ $-1.694M ▼
Q2-2024 $-2.102M $-1.639M $-1.017M $2.972M $317.38K $-1.656M

Five-Year Company Overview

Income Statement

Income Statement Sharps Technology’s historical income statement looks like an early‑stage company: essentially no product revenue yet and recurring operating losses. The business has been spending to build its platform and capabilities without meaningful sales coming in the door. Losses to date appear modest in absolute terms but large on a per‑share basis because of the reverse stock splits. Overall, the past few years show a pre‑commercial, investment phase rather than a mature operating business.

Balance Sheet

Balance Sheet The reported balance sheet up to 2024 is very small, with limited assets, little or no cash shown, no traditional debt, and only a thin layer of equity. That picture is typical of a company that has been capital‑constrained and reliant on raising fresh equity to fund operations. However, the narrative for 2025 describes a huge capital infusion and the creation of a very large Solana crypto treasury. If executed as described, the balance sheet would shift from being underpowered to being dominated by a single, volatile digital asset. This brings financial strength in the form of liquidity, but also concentration and market‑value risk tied to Solana.

Cash Flow

Cash Flow Historically, cash flow has been one‑sided: money going out for operating expenses, with no operating inflows from a commercial business. Free cash flow has been negative, reflecting that the company is still building its platform. Capital spending has been minimal, so most of the cash burn is likely salaries, development, and overhead. Going forward, the story changes: cash flow could come from two different engines—staking income and value changes in the Solana treasury, plus future margins from medical device distribution. That mix could make cash flows more substantial but also more volatile and heavily influenced by crypto markets.

Competitive Edge

Competitive Edge Sharps is repositioning itself from a niche syringe innovator with limited scale into a hybrid med‑tech distributor backed by a large digital‑asset war chest. On the healthcare side, it has differentiated safety syringe designs and prefillable polymer syringe technology, plus distribution partnerships that give it reach in North America and internationally. A multi‑year SoloGard supply agreement, if executed well, could provide important commercial validation. On the financial side, the large Solana treasury gives it more capital flexibility than most small healthcare peers. At the same time, this new model is unusual: the company now competes with traditional, steady med‑device players while carrying a balance sheet and earnings profile that are partly driven by crypto asset performance, regulatory views on digital assets, and the strength of its partner network. The competitive edge is therefore a mix of product IP, distribution access, and financial firepower—but the strategy is still early and unproven at scale.

Innovation and R&D

Innovation and R&D Sharps’ core technical innovations are in safety and prefillable syringes designed to reduce needlestick injuries, prevent reuse, cut medicine waste, and improve durability versus glass. These are real pain points in healthcare and can be attractive to hospitals, pharma companies, and global health buyers. More recently, the company’s focus has shifted from pure R&D toward a broader innovation model: combining its legacy IP, outsourced manufacturing partners, and global distribution with a sophisticated digital‑asset treasury. Innovation now includes structuring end‑to‑end drug delivery solutions for pharma clients and actively managing a large Solana position through institutional custody and staking platforms. A key open question is how much emphasis will remain on traditional product development versus financial and commercial innovation. The direction of future R&D spending and pipeline announcements will be important signals.

Summary

Up to 2024, Sharps Technology looked like a very small, pre‑revenue healthcare company: thin assets, ongoing losses, negative cash flow, and no established commercial base. The described 2025 pivot radically changes that profile, at least on paper. The business is transforming into a medical device distributor built on legacy safety syringe technology, bolstered by global distribution partnerships, and underpinned by a large, concentrated Solana crypto treasury. This brings clear strengths—access to capital, differentiated products, and the ability to pursue deals—alongside notable risks, including dependence on a single digital asset, the need to prove out the new distribution‑led model, and reputational and regulatory complexity from blending crypto with healthcare. Historical financials show an early‑stage, capital‑hungry company, while the narrative points to a very different, more financially muscular but less predictable future. The gap between those two pictures highlights how much execution and market conditions will matter from here.

NEWS

October 9, 2025 · 7:00 AM UTC

Sharps Technology Expands Digital Asset Treasury Strategy with Coinbase

Read more

October 2, 2025 · 7:00 AM UTC

Sharps Technology Announces $100 Million Stock Repurchase Program

Read more

September 29, 2025 · 7:00 AM UTC

Crypto.com and Sharps Technology Partner to Strengthen Solana Ecosystem Growth Through Institutional Treasury Solutions

Read more

September 23, 2025 · 7:00 AM UTC

Sharps Technology and Jupiter Exchange Announce Staking Partnership to Accelerate Solana Adoption

Read more

September 16, 2025 · 7:00 AM UTC

Sharps Technology and BONK Announce Staking Collaboration, Bridging Institutional Capital and Web3 Culture

Read more